Denali Therapeutics Inc. (DNLI)
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
